
Possibility of improving muscle loss was also confirmed… Clinical application to the US FDA in February next year
Celltrion announced that it plans to confirm the weight loss effect of CT-G32/SCO-940, a quadruple action obesity treatment candidate, in non-clinical trials and submit a clinical trial plan to the US FDA in February next year.
AI-generated summary
Celltrion is developing CT-G32/SCO-940, a next-generation quadruple-action obesity treatment candidate, and is designed to simultaneously target four hormonal pathways: GLP-1, GIP, glucagon, and amylin.
Celltrion [068270] announced on the 4th that the weight loss effect of 'CT-G32/SCO-940', a next-generation quadruple action obesity treatment candidate, was confirmed in non-clinical trials.
Celltrion announced the results of non-clinical research on CT-G32/SCO-940 with Japan's SCOHIA Pharma at the conference 'TIDES Europe' held in Amsterdam, Netherlands until the 5th.
This agent is designed to simultaneously target four hormonal pathways, including glucagon-like peptide-1 (GLP-1), insulinotropic peptide (GIP), glucagon, and amylin.
Celltrion reported that in animal evaluation models, CT-G32/SCO-940 showed a greater weight loss effect than the triple-action obesity treatment drug 'Retatrutide'.
They also added that the possibility of improving muscle loss, which is pointed out as a drawback of obesity treatment drugs, was confirmed as the reduction in lean body mass, which is calculated by subtracting fat from body weight, is small.
Celltrion explained that the effect of lowering excessive blood insulin levels was also observed, showing the possibility of expanding the indications beyond obesity treatment to metabolic disease treatment.
Pharmacokinetic evaluation on primates showed that exposure to the drug in the body was maintained for a long period of time, making it possible to administer it once a week.
Celltrion plans to submit an clinical trial plan (IND) for CT-G32/SCO-940 to the U.S. Food and Drug Administration (FDA) by February next year and begin administering the drug to patients as early as the second quarter of next year.
A Celltrion official said, “We plan to develop CT-G32/SCO-940 as a first-in-class new drug that can compensate for muscle loss during weight loss,” and plan to foster this substance as a core pipeline in the field of obesity and metabolic diseases.
He added, “We will advance into clinical trials without a hitch and develop it as a next-generation treatment that encompasses improvement of body composition and metabolism.”
AI outlook — possibilities, not facts
Celltrion will submit the CT-G32/SCO-940 clinical trial plan (IND) to the U.S. FDA by February next year.
Very likely · Within months
Patient administration of CT-G32/SCO-940 will begin as early as the second quarter of next year.
Likely · Within months

South Korean stocks opened sharply higher Wednesday, with the KOSPI rising 2.43 percent to 5,786.13, driven by tech share gains as investors awaited U.S. midterm election results. Overnight, Wall Street's Nasdaq gained 0.83 percent on strong chip shares.

Hanmi Semiconductor Chairman Kwak Dong-shin will acquire an additional 10 billion won worth of treasury stocks with his own money. As a result, Chairman Kwak has purchased a total of KRW 80.2 billion in treasury stocks starting in 2023, and acquired KRW 26.7 billion this year alone. Once this acquisition is completed, Chairman Kwak's shareholding will increase to 33.69%.

Coupang Inc. Chairman Kim Beom-seok said that although the company recorded an operating loss of KRW 642.3 billion in the third quarter, making a deficit for three consecutive quarters, this was due to temporary cost burden and short-term investment rather than structural problems, and predicted that product commerce margins next year will be close to the level before the personal information leak incident.

Hanwha Investment & Securities raised Jeju Air's target stock price from 6,500 won to 7,500 won in accordance with its forecast for next year's operating profit growth. Jeju Air turned a profit in the third quarter with an operating profit of 54.9 billion won, and the previous day's closing price was 5,720 won.

Daishin Securities lowered its target stock price from 530,000 won to 500,000 won, reflecting lower forecasts for North American battery shipments and small battery profitability, despite LG Energy Solutions' performance improvement forecast for next year. There is room for an increase of about 48% compared to the previous day's closing price.

KB Securities lowered Poongsan's target stock price from 112,000 won to 90,000 won and maintained its investment opinion of 'buy'. It is expected that the new copper sector will slow down due to the unfavorable macro environment, such as the strong won and the stabilization of copper price declines, and the recovery of delivery dates in the defense industry will be delayed to 2027.